[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.175.236. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
December 2015

Pneumococcal Prevention Gets Older and Wiser

Author Affiliations
  • 1National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
JAMA Intern Med. 2015;175(12):1897-1898. doi:10.1001/jamainternmed.2015.6133

Pneumococcus, or Streptococcus pneumoniae, the “captain of the men of death” in the parlance of Sir William Osler, has killed millions of people while repeatedly frustrating clinicians, vaccine experts, and epidemiologists. The advent of effective antibiotics did not eliminate deaths from pneumococcal disease. Pneumococcal morbidity has remained substantial among the elderly population even though most have received the 23-valent pneumococcal polysaccharide vaccine (PPSV-23). Diagnostic tests for pneumonia are relatively insensitive and nonspecific.1 Thus, it is difficult to evaluate the efficacy of pneumococcal vaccines against pneumonias that do not lead to detectable bloodstream infection.

First Page Preview View Large
First page PDF preview
First page PDF preview
×